Abbott Laboratories
Abbott Laboratories (NYSE: ABT) discovers, develops, manufactures, and sells healthcare products worldwide to healthcare providers, institutions, government agencies, distributors, retailers, and consumers. Its four reportable segments are Established Pharmaceutical Products, which sells branded generic medicines… From the company’s description.
In fiscal 2025, Abbott Laboratories reported revenue of $44.33B, up 5.7% from fiscal 2024, and net income of $6.52B. Its operating margin was 18.2%, and operations generated $9.57B in cash. Over the twelve months to Jun 30, 2026, revenue was $46.59B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Abbott Laboratories does
In the company’s own words
Abbott Laboratories (NYSE: ABT) discovers, develops, manufactures, and sells healthcare products worldwide to healthcare providers, institutions, government agencies, distributors, retailers, and consumers. Its four reportable segments are Established Pharmaceutical Products, which sells branded generic medicines mainly outside the United States; Diagnostic Products, including laboratory, molecular, point-of-care, and rapid testing systems; Nutritional Products, covering pediatric and adult nutrition; and Medical Devices, including cardiovascular, diabetes care, continuous glucose monitoring, and neuromodulation products. Major brands include Similac, Ensure, FreeStyle Libre, Alinity, MitraClip, and Creon. Abbott employs approximately 115,000 people as of December 31, 2025, and operates in more than 160 countries. In November 2025, it agreed to acquire Exact Sciences, a cancer diagnostics company, subject to customary closing conditions. Its website is www.abbott.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- ABBOTT PARK, IL
- Fiscal year end
- December
- CIK
- 1800
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Abbott Laboratories — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Abbott Laboratories · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Abbott Laboratories’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Abbott Laboratories’s bonds, as funds hold them
Funds report holding 17 issues of Abbott Laboratories’s debt, $4.94B at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.43%, maturing 2026 to 2066.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Abbott Laboratories and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Abbott Laboratories's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Abbott Laboratories's last four quarterly filings that the numbers alone won't show?”